Introduction: Recent data suggest metformin (Met) has antineoplastic properties in different type of cancer. Effects of Met have never been investigated in NET.
Aim(s): To determine the role of Met on RFS in NET patients (pts).
Materials and methods: A retrospective analysis was conducted comparing NET pts with recent diagnosis (< 1 yr) of diabetes mellitus, with HbA1c≤7%, treated with Met (group A) to non-diabetic NET pts without Met (group B) with comparable clinical and pathological characteristics. RFS was evaluated by Kaplan-Meier analysis
Conference: 11th Annual ENETS Conference 2014 (2014)
Category: Medical treatment - Others
Presenting Author: Francesca Marciello
, Del Prete M
, Marotta V
, Ramundo V
, Buonomano P
, Carratù A C
, De Luca di Roseto C
, Modica R
, Picillo E
, Colao A
, Faggiano A
To read results and conclusion, please login ...
Further abstracts you may be interested in